Source: Annual Congress 2006 - Lung cancer treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Korn, R. G. Meyer, P. Micke, C. Huber, T. Wölfel, R. Buhl (Mainz, Germany; Uppsala, Sweden). Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC). Eur Respir J 2006; 28: Suppl. 50, 4817

Member's Comments

No comment yet.

Related content which might interest you: XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Lung cancer Source: Respipedia Article Year: 2018 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012